| Name | Title | Contact Details |
|---|---|---|
Shane Edmonds |
Chief Technology Officer | Profile |
Since 1983, Schulman has provided the research community with IRB review services of the highest quality. In establishing the IRB, our founders sought to promote clinical research by helping to safeguard the rights and welfare of clinical research subjects. Schulman’s team of dedicated professionals seeks to provide timely, quality services based on the foundation of respect for persons, beneficence and justice. Through continuous quality improvement and rigorous training on human subject protection, Schulman provides thorough, ethical, responsive and thoughtful review of research studies. By combining impeccable review standards, savvy industry insight, responsive customer service and innovative technological solutions, Schulman creates a review experience that goes beyond the expected. We look forward to continued collaboration with our colleagues in North America and around the world as we uphold our mission to protect the rights and welfare of clinical research subjects.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex`s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product, Tru Niagen® — available at www.truniagen.com and through partnerships with global retailers and distributors.
Aid in Recovery is a addiction treatment center referral service.
InsideTracker is a personalized health analytics company founded by leading scientists, physicians, nutritionists and exercise physiologists from MIT, Harvard and Tufts University. The InsideTracker platform analyses and tracks key biochemical and phys...
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."